Bank of America cuts target for Merck & Co. stock to USD 163.00

Published on 10/13/2026 at 16:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter sales reached USD 16.60 billion on August 4, 2026. Merck & Co. stock costs EUR 128.91 on October 13, 2026.

Target and operating figures

Bank of America lowered its Merck target from USD 166.00 to USD 163.00 on October 9, 2026.
Second-quarter sales reached USD 16.60 billion versus USD 16.30 billion in the first quarter of 2026.
Merck & Co. stock costs EUR 128.91 at Lang & Schwarz on October 13, 2026 at 4:33 p.m. CEST.
Merck had a USD 356.0 billion market capitalization and a P/E ratio of 115.49 on October 13, 2026.

Extreme Makroaufnahme einer Glasampulle mit Wassertropfen und Metallverschluss — Makroaufnahme einer Impfstoffampulle veranschaulicht Kerngeschäft von Merck & Co. Inc., ISIN US58933Y1055, im Detail, Illustration mit AI erstellt.

Bank of America cut its Merck target from USD 166.00 to USD 163.00 on October 9, 2026, while keeping a Buy rating, according to Aktiencheck. Against the USD 144.15 NYSE price on October 13, 2026, the new target lies 13.08 percent higher. Merck stock was at EUR 128.91 at Lang & Schwarz on October 13, 2026 at 4:33 p.m. CEST.

Sales reached USD 16.60 billion

Merck & Co. reported USD 16.60 billion in worldwide sales for the second quarter of 2026, compared with USD 16.30 billion in the first quarter of 2026. The sequential increase was 1.84 percent, based on the figures presented by the company on August 4, 2026.

NYSE price stays below its high

On the NYSE, Merck last traded at USD 144.15 on October 13, 2026 at 10:38 a.m. ET. The session range was USD 143.50 to USD 145.93, with 1,119,796 shares traded against an average volume of 9,850,245 shares.

The 52-week NYSE range was USD 82.01 to USD 156.92. The latest home-market price stood 8.14 percent below the 52-week high, while the current session price remained inside that range.

Valuation and October 29 results

Merck had a USD 356.0 billion market capitalization and a P/E ratio of 115.49 on October 13, 2026. Its trailing dividend yield was 2.00 percent. The next quarterly results conference call is scheduled for October 29, 2026, according to Merck & Co..

Comparison with peers

Merck & Co. (NYSE, USD): P/E 115.49, market capitalization USD 356.0 billion

Pfizer (NYSE, USD): minus 0.21 percent, P/E 37.48, market capitalization USD 161.5 billion

Bristol-Myers Squibb (NYSE, USD): minus 1.82 percent, P/E 12.46, market capitalization USD 115.5 billion

Price and reporting date

Merck stock was at EUR 128.91 at Lang & Schwarz on October 13, 2026 at 4:33 p.m. CEST. The next company reporting date is October 29, 2026. The further course of trading is shown by the continuously updated real-time quote of Merck & Co. stock.